Cadherin 11促进免疫抑制与细胞外基质沉积以支持小鼠胰腺肿瘤生长及吉西他滨耐药
该研究在胰腺导管腺癌(PDAC)小鼠模型中探讨靶向黏附分子CDH11的作用。CDH11在癌相关成纤维细胞(CAF)中高表达,敲除或抑制CDH11可减少肿瘤生长、增加吉西他滨疗效并显著延长小鼠生存期。CDH11通过促进免疫抑制和细胞外基质沉积支持肿瘤进展,可能成为胰腺癌治疗靶点。
要点
- CDH11在胰腺癌CAF中高表达,敲除可延长KPC小鼠生存期。
- CDH11缺失增加抗原呈递标志物和淋巴细胞,减少免疫抑制与ECM成分。
- CDH11抑制剂联合吉西他滨可增强疗效,且其作用依赖T、B细胞。
核心结论
- 敲除或抑制CAF表达的CDH11可减少胰腺肿瘤生长、增强吉西他滨反应并显著延长小鼠生存期。
- CDH11通过促进免疫抑制和细胞外基质沉积支持胰腺肿瘤进展,可能成为治疗靶点。
研究设计与样本
- 比较人胰腺炎与胰腺癌组织及细胞中CDH11 mRNA和蛋白水平,以及人和小鼠胰腺病变与正常组织中的CDH11蛋白。
- 将p48-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+(KPC)小鼠与CDH11敲除小鼠杂交并观察子代生存时间。
- 对胰腺进行组织学、免疫组化、(单细胞)RNA测序及成像质谱流式分析。
- 部分小鼠注射PD1抗体或吉西他滨并监测生存;将KPC来源胰腺癌细胞皮下接种至Cdh11+/+和Cdh11-/-小鼠观察肿瘤生长。
- 将KPC来源mT3细胞皮下接种至Cdh11+/+(C57BL/6J)小鼠,给予CDH11抗体、吉西他滨或CDH11小分子抑制剂SD133并监测肿瘤生长。
主要发现
- CDH11 mRNA和蛋白在CAF中显著高于胰腺癌上皮细胞、人/小鼠胰腺癌细胞系或免疫细胞。
- KPC/Cdh11+/-和KPC/Cdh11-/-小鼠生存期显著长于KPC/Cdh11+/+小鼠。
- KPC/Cdh11+/+小鼠中基质活化标志物完全包绕胰腺上皮内瘤变,而KPC/Cdh11+/-和KPC/Cdh11-/-小鼠中包绕不完全且肿瘤中心FOXP3+细胞更少。
- 与KPC/Cdh11+/+小鼠肿瘤相比,KPC/Cdh11+/-小鼠肿瘤抗原加工与呈递标志物增加、淋巴细胞及相关细胞因子增多、细胞外基质成分减少、免疫抑制相关标志物和细胞因子降低。
- PD1抗体未延长携带0、1或2个Cdh11等位基因的KPC小鼠生存期;吉西他滨仅在联合CDH11抗体时延长KPC/Cdh11+/-和KPC/Cdh11-/-小鼠生存期或减少mT3移植Cdh11+/+小鼠皮下肿瘤生长。
临床怎么用
- CDH11可作为胰腺癌潜在治疗靶点,抑制CDH11可能增强吉西他滨疗效。
- 靶向CDH11的策略可能需依赖完整T、B细胞免疫功能。
- PD1抗体单药在CDH11不同等位基因状态下未显示生存获益,联合策略需进一步研究。
局限性
- 研究主要基于小鼠模型和皮下移植瘤,结果需在人体临床试验中验证。
- CDH11小分子抑制剂SD133的疗效仅在特定免疫健全小鼠模型中观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Pancreatic ductal adenocarcinomas (PDACs) are characterized by fibrosis and an abundance of cancer-associated fibroblasts (CAFs). We investigated strategies to disrupt interactions among CAFs, the immune system, and cancer cells, focusing on adhesion molecule CDH11, which has been associated with other fibrotic disorders and is expressed by activated fibroblasts. METHODS: We compared levels of CDH11 messenger RNA in human pancreatitis and pancreatic cancer tissues and cells with normal pancreas, and measured levels of CDH11 protein in human and mouse pancreatic lesions and normal tissues. We crossed p48-Cre;LSL-KrasG12D/+;LSL-Trp53R172H/+ (KPC) mice with CDH11-knockout mice and measured survival times of offspring. Pancreata were collected and analyzed by histology, immunohistochemistry, and (single-cell) RNA sequencing; RNA and proteins were identified by imaging mass cytometry. Some mice were given injections of PD1 antibody or gemcitabine and survival was monitored. Pancreatic cancer cells from KPC mice were subcutaneously injected into Cdh11+/+ and Cdh11-/- mice and tumor growth was monitored. Pancreatic cancer cells (mT3) from KPC mice (C57BL/6), were subcutaneously injected into Cdh11+/+ (C57BL/6J) mice and mice were given injections of antibody against CDH11, gemcitabine, or small molecule inhibitor of CDH11 (SD133) and tumor growth was monitored. RESULTS: Levels of CDH11 messenger RNA and protein were significantly higher in CAFs than in pancreatic cancer epithelial cells, human or mouse pancreatic cancer cell lines, or immune cells. KPC/Cdh11+/- and KPC/Cdh11-/- mice survived significantly longer than KPC/Cdh11+/+ mice. Markers of stromal activation entirely surrounded pancreatic intraepithelial neoplasias in KPC/Cdh11+/+ mice and incompletely in KPC/Cdh11+/- and KPC/Cdh11-/- mice, whose lesions also contained fewer FOXP3+ cells in the tumor center. Compared with pancreatic tumors in KPC/Cdh11+/+ mice, tumors of KPC/Cdh11+/- mice had increased markers of antigen processing and presentation; more lymphocytes and associated cytokines; decreased extracellular matrix components; and reductions in markers and cytokines associated with immunosuppression. Administration of the PD1 antibody did not prolong survival of KPC mice with 0, 1, or 2 alleles of Cdh11. Gemcitabine extended survival of KPC/Cdh11+/- and KPC/Cdh11-/- mice only or reduced subcutaneous tumor growth in mT3 engrafted Cdh11+/+ mice when given in combination with the CDH11 antibody. A small molecule inhibitor of CDH11 reduced growth of pre-established mT3 subcutaneous tumors only if T and B cells were present in mice. CONCLUSIONS: Knockout or inhibition of CDH11, which is expressed by CAFs in the pancreatic tumor stroma, reduces growth of pancreatic tumors, increases their response to gemcitabine, and significantly extends survival of mice. CDH11 promotes immunosuppression and extracellular matrix deposition, and might be developed as a therapeutic target for pancreatic cancer.
引用
- Peran I, Dakshanamurthy S, McCoy MD, et al. Cadherin 11 Promotes Immunosuppression and Extracellular Matrix Deposition to Support Growth of Pancreatic Tumors and Resistance to Gemcitabine in Mice. Gastroenterology. 2020. PMID: 33307028. doi:10.1053/j.gastro.2020.11.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。